[Elsevier] The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial

manute.bol Post time Half hour(s) ago | Show all posts |Read mode

This post will be closed automatically in 2026-08-01 16:26

Reward10points

journal：The Lancet Gastroenterology & Hepatology

Authors：Prof Mazen Noureddin, MD; Prof Winston Dunn, MD; Rashmee Patil, MD; Dimple Desai, MD; Rohit Puskoor, MD; Jaehee Shin, MS; Dennis To, PhD; Adam C Bell, PhD; Daniel R Lee, MS; Yen-Huei Lin, PhD; Seulki Lee, PhD

Published date：2026-8-21

DOI：10.1016/S2468-1253(26)00130-5

PDF link：https://www.sciencedirect.com/science/article/pii/S2468125326001305/pdf

Article link: https://doi.org/10.1016/S2468-1253(26)00130-5

Article Source：Elsevier BV。

Remark：

You can support us by donating, we would be very grateful.

Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

manute.bol Lv.4

Senior Member

post
reply
points
11480

[Elsevier] The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial Copy

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial